Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-09-24
2008-11-04
Maier, Leigh C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07446100
ABSTRACT:
The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CFS of G-CSF.
REFERENCES:
patent: 4141973 (1979-02-01), Balazs
patent: 4725585 (1988-02-01), Wenge et al.
patent: 5079236 (1992-01-01), Drizen et al.
patent: 5646129 (1997-07-01), Callegaro et al.
patent: 5767106 (1998-06-01), Turley et al.
patent: 5811410 (1998-09-01), Falk et al.
patent: 5817644 (1998-10-01), Gustafson
patent: 5827834 (1998-10-01), Falk et al.
patent: 5914314 (1999-06-01), Falk et al.
patent: 6013641 (2000-01-01), Lussow et al.
patent: 6069135 (2000-05-01), Falk et al.
patent: 6432405 (2002-08-01), Weinberg et al.
patent: 1205031 (1986-05-01), None
patent: 91/04058 (1991-04-01), None
patent: 93/16732 (1993-09-01), None
patent: 96/16733 (1993-09-01), None
patent: 94/23725 (1994-10-01), None
patent: 95/30423 (1995-11-01), None
patent: 96/05845 (1996-02-01), None
patent: 96/06622 (1996-03-01), None
patent: 97/03699 (1997-02-01), None
patent: 97/15330 (1997-05-01), None
patent: 97/25051 (1997-07-01), None
patent: 98/13024 (1998-04-01), None
patent: 98/17320 (1998-04-01), None
patent: 98/52590 (1998-11-01), None
patent: 99/55230 (1999-11-01), None
Matrosova, V. et al “Hyaluronic acid facilitates the recovery of hematopoiesis . . . ” Stem Cells (2004) vol. 22, pp. 544-555.
O'Reilly, M. et al “Indomethacin augments granulocyte-macrophage . . . ” Exp. Hematol. (1990) vol. 18, No. 9, pp. 974-978.
Gowland et al.; “Marked Enhanced Efficacy of Cyclosporin When Combined With Hyaluronic Acid Evidence From Two T Cell-Mediated Modaels”; Clinical Drug Investigation 11(4): 245-250 (1996).
Toole; “Hyaluronan and its binding proteins, the hyaladherins”; Curr. Opin. Cell. Biol. 2: 839-844 (1990).
Toole; “Development role of hyaluronate”; Conn. Tiss. Res. 10: 93-100 (1982).
Entwistle et al.; “Cloning and characterization of the gene encoding the hyaluronan receptor RHAMM; the role of a secreted isoform in the regulation of focal adhesion formation”; Gene 163: 233-238 (1995).
Yang et al.; “Overexpression of the hyaluronan receptor RHAMM is transforming, and is required for H-ras transformation”; Cell 82: 19-28 (1995).
Masellis-Smith et al.; “Hyaluronan-development motility of B cells and leukemic plasma cells in multiple myeloma: Alternate usage of RHAMM and CD44”; Blood 87: 1891-1899 (1996).
Turley et al.; “Expression and function of a receptor for hyaluronan-mediated motility (RHAMM) on normal and malignant B lymphocytes”; Blood 81: 446-453 (1993).
Pilarski et al.; “Regulation expression of a receptor for hyaluronan-mediated motility RHAMM on human thymocytes and T cells”; J. Immunol. 150: 4292-4302 (1993).
S. K.B. et al.; “The Regulation of Sperm Motility by a Novel Hyaluronan Receptor”; Fertility and Sterility 61: 935-940 (1994).
Turley et al.; “Astrocyte and microglial motility in vitro is functionally dependent on the hyaluronan receptor RHAMM”; Glia, 12: 68-80 (1994).
Golub et al.; Immunology A Synthesis 2:205 (1991).
Kuby; Immunology 3:50 (1997).
Weaver et al.; “An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy”; Blood 86: 3961-3969 (1995).
Boiron et al.; “Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF)”; Bone Marrow Transplantation 12: 49-55 (1993).
Schiller et al.; “Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma”; Blood 86: 390-397 (1995).
Hamann et al.; Journal of Immunology 154(8): 4073-80 (1995).
Han et al.; Journal of Cellular Physiology 168 (1): 97-104 (1996).
Alho et al.; J. Cell. Biol. 108: 1557-1565 (1989).
Kelly et al.; J. Dermatol. Surg. Oncol. 16 (11): 1039-1042 (1990).
Martindale The Extra Pharmacopoeia, Reynolds et al. Editors, The Pharmaceutical Press, London, pp. 234-235 (1982).
The Merch Index, Ninth Edition, Merch & Co., Inc., Rahway, New Jersey, p. 407, No. 3058 (1976).
Trabucchi et al., Int. J. Tiss. Reac., VIII(6): 533-554 (1986).
Webster's Ninth New College Dictionary, Merriam-Webster Inc., Springfield, Massachusetts, p. 1256 (1990).
West et al.; Experimental Cell Research 183: 179-196 (1989).
Maier Leigh C
Pillsbury Winthrop Shaw & Pittman LLP
The Governors of the University of Alberta
LandOfFree
Methods for cell mobilization using in vivo treatment with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for cell mobilization using in vivo treatment with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for cell mobilization using in vivo treatment with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4047858